BiomeSense

BiomeSense

At-home biosensor with AI microbiome analytics

Overview

BiomeSense provides an integrated platform for gut microbiome analysis, combining an at-home biosensor for continuous monitoring with a cloud-based, AI-powered data analysis system. Users collect longitudinal microbiome data at home, which is securely transmitted to the cloud where AI algorithms identify patterns and track changes over time. The company differentiates itself by offering a low-cost, large-scale hardware-and-software solution designed for clinical trials and consumer health, rather than relying on single-time-point tests. Its goal is to help researchers and product teams use microbiome data to understand health and disease and advance precision medicine.

Significant Headcount Growth

About BiomeSense

Simplify's Rating
Why BiomeSense is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

Biotechnology

Healthcare

Company Size

11-50

Company Stage

Seed

Total Funding

$5.4M

Headquarters

Chicago, Illinois

Founded

2018

Get referred to BiomeSense

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BiomeSense won a $676,980 NIH SBIR/STTR award on June 16, 2026.
  • The August 2024 Pendulum study validated GutLab in a live longitudinal trial.
  • Open roles for partnerships, engineering, and research signal active scaling in August 2026.

What critics are saying

  • LinkedIn showed only 17 employees in April 2026, limiting execution depth.
  • Revenue depends on grants and pilots; the June 2026 NIH award does not prove commercialization.
  • If GutLab stays costly or clunky versus Illumina sequencing and stool-kits, 2027 demand stalls.

What makes BiomeSense unique

  • GutLab and MetaBiome combine home sampling with AI bioinformatics, updated July 27, 2026.
  • BiomeSense owns eight patents around stool collection and processing, strengthening hardware defensibility.
  • Its continuous longitudinal microbiome data is harder to replicate than single-sample sequencing workflows.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$5.4M

Below

Industry Average

Funded Over

2 Rounds

Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Meet Average

Industry standards

$3.3M
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood
$3M
BiomeSense

Benefits

Health Insurance

Stock Options

Paid Vacation

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

6%
Crain Communications
Oct 20th, 2025
BiomeSense raises $7M for gut tests

Chicago-based startup BiomeSense has secured $7M in funding to advance technology aimed at making gut microbiome testing as common as genetic testing.

The Business Journals
May 10th, 2023
BiomeSense CEO describes 'ups and downs' of scaling a biotech startup in Chicago

'Our seed round was meant to get us to a certain milestone, but because of Covid, we weren't able to get there.' BiomeSense CEO gets candid about the Chicago biotech starutps 'seed-2' financing.

Recently Posted Jobs

Sign up to get curated job recommendations

BiomeSense is Hiring for 3 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →